|

MEN1703 Clinical Trials

1 actively recruiting trial

Also known as: Dapolsertib hydrochloride, SEL24

Pipeline

Phase 2: 1

Top Sponsors

  • Ryvu Therapeutics SA1

Indications

  • Non-hodgkin Lymphoma,B Cell1
  • Cancer1

Other1 trial

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.